ライフサイエンスコーパス: oncology

1 uch clinically relevant signatures in immuno-oncology.

2 nd challenges to, the use of PARPis in neuro-oncology.

3 challenges to realize the goal of precision oncology.

4 and drug response, and may advance precision oncology.

5 atic cancer, one of the major unmet needs in oncology.

6 ve validated GSTO1 as an impactful target in oncology.

7 ccelerate future studies of precision cardio-oncology.

8 inical application for IVIM perfusion MRI is oncology.

9 wards data science-driven liquid biopsies in oncology.

10 sease, are areas of considerable interest in oncology.

11 y trial has historically been predominant in oncology.

12 lied to predict novel therapeutic targets in oncology.

13 ority as other aspects of palliative care in oncology.

14 s been a longstanding objective in precision oncology.

15 f hope with respect to its applicability for oncology.

16 ative for an intersecting discipline: cardio-oncology.

17 aluated clinically as a treatment option for oncology.

18 rkers presents a major obstacle in precision oncology.

19 active and previously unrecognized target in oncology.

20 s a key area in the development of precision oncology.

21 o the A(2A) AR, an emerging target in immuno-oncology.

22 remains a major unsolved problem in clinical oncology.

23 mpeting endogenous RNA (CeRNA) hypothesis in oncology.

24 continuity of care in the field of surgical oncology.

25 lications for using nanotechnology in immuno-oncology.

26 all areas of particular relevance to immuno-oncology.

27 drugs and will have major impacts on immuno-oncology.

28 tasets that further fuel the (r)evolution in oncology.

29 ng and prediction of outcome in personalized oncology.

30 at has long been pursued as a drug target in oncology(1), and more recently in immunotherapy(2,3) and

31 as been a major breakthrough in the field of oncology, a fact recognized by the 2018 Nobel Prize in P

32 inhibitors are being pursued as therapies in oncology, a large prospective clinical cardiovascular ou

33 crolibulin combined with cytotoxic or immune-oncology agents.

34 2, open-label, single-arm, multicentre, Rare Oncology Agnostic Research (ROAR) basket trial in patien

35 The American Society of Clinical Oncology, American Society for Radiation Oncology, and S

36 ngoing pay-for-performance (P4P) program for oncology and changes in the prescribing of evidence-base

37 Participants were recruited from medical oncology and colorectal cancer surgery departments in th

38 intracellular delivery is required, such as oncology and gene therapy.

39 ematologie - German Association of Pediatric Oncology and Haematology pediatric cooperative groups, i

40 ematologie - German Association of Pediatric Oncology and Haematology.

41 Survival in critically ill oncology and hematology patients with sepsis improved si

42 ith representation from pediatric hematology/oncology and HSCT, pediatric infectious diseases (includ

43 using predictive multivariate signatures in oncology and in other therapeutic areas.

44 sed HeLa cells and screened 231 FDA-approved oncology and natural substance drugs included in two NCI

45 applications in many fields, particularly in oncology and neuroradiology.

46 The American Society of Clinical Oncology and Ontario Health (Cancer Care Ontario) NSCLC

47 implementation of AI platforms in radiation oncology and provide our perspective on how these platfo

48 red in other clinical applications including oncology and rheumatoid arthritis, could also be exploit

49 The European Society of Gynaecological Oncology and the European Society for Paediatric Oncolog

50 rs delineate the scope of practice in cardio-oncology and the proposed training requirements, as well

51 immunology and targeted therapy has reshaped oncology, and in many cases, reshaped the course of once

52 earch on Cancer, and the Veneto Institute of Oncology, and Italian Association for Cancer Research.

53 lgian Cooperative Trial Group for Hematology Oncology, and Janssen Research and Development.

54 date, most of them for metabolic disease or oncology, and more than 10 potentially first-in-class pe

55 ations including drug repurposing, precision oncology, and new drug development, through different da

56 cal Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology convened an E

57 Association, American Society for Radiation Oncology, and Society of Urologic Oncology to conduct a

58 rategies are increasingly important in neuro-oncology, and the elucidation of escape mechanisms that

59 the future of macrophage-based therapies in oncology are included.

60 serves as a roadmap toward confirming cardio-oncology as a subspecialty in medicine.

61 many others are in clinical development for oncology as well as other therapeutic indications.

62 interest in drug discovery, particularly in oncology, as discrimination between healthy and malignan

63 The American Society of Clinical Oncology (ASCO) and the European Society for Medical Onc

64 ng on the most urgent research priorities in oncology.ASCO's 2020 Advance of the Year-Refinement of S

65 iew of cancer nanomedicines in four emerging oncology-associated fields: (i) gene therapy, (ii) immun

66 ement, hepatobiliary, colorectal, gynecology oncology, bariatric, general, and urological surgery wer

67 in inhibitors under clinical development for oncology bind to each of the eight bromodomains with sim

68 sed on premarket and postmarket policies for oncology biosimilars before most of these drugs received

69 ng with therapeutic than for supportive care oncology biosimilars.

70 y factors preventing the effective launch of oncology biosimilars.

71 to review medical products and label PROs in oncology can improve communication between stakeholders

72 integration of palliative care into routine oncology care and describes best practices recognized fo

73 at specialty palliative care integrated into oncology care improves patient and health system outcome

74 specific domains within pediatric palliative oncology care including family-centered communication, a

75 The long-term effect of COVID-19 on oncology care worldwide is unknown, but immediate therap

76 family bereavement support within pediatric oncology care, including addressing the differing needs

77 that early palliative care, integrated with oncology care, not only improves these key outcomes but

78 easures related to integrated palliative and oncology care.

79 treatment optimization in low-disease-burden oncology care.

80 = 128) were recruited from 13 United States oncology centers throughout the Translational Research i

81 uated when applying nanotechnology to immuno-oncology challenges.

82 consecutively ascertained patients with CRC (oncology clinic cohort), unselected for familial risk.

83 83.3% of high-risk patients with CRC/EC and oncology clinic CRC patients with high-penetrance PVs, r

84 s in high-risk (89.3% v 85.7%; P = .712) and oncology clinic patients (96.6% v 96.6%; P = 1.000), alt

85 eration sequencing in inherited diseases and oncology, clinical laboratories are evaluating the use o

86 th more primary palliative care delivered by oncology clinicians.

87 , there has been a remarkable rise of cardio-oncology clinics and service lines.

88 24 academic research centres, hospitals, and oncology clinics in 23 countries.

89 trial conducted at 91 US urology and medical oncology clinics that enrolled 478 men aged 50 to 80 yea

90 t and providing more oversight to outpatient oncology clinics.

91 firm this role, we screened the NIH Approved Oncology collection for chemical-genetic interactions wi

92 Our screen provides a resource for the neuro-oncology community and identified miR-1300 as a novel re

93 ts for solid tumor targeting by high-potency oncology compounds.

94 he V Foundation, the Pacific Pediatric Neuro-Oncology Consortium Foundation, the Pediatric Brain Tumo

95 Within the Pacific Pediatric Neuro-Oncology Consortium, we assessed the safety and efficacy

96 The American Society of Clinical Oncology convened an Expert Panel of medical oncology, s

97 Radiation Oncology, and Society of Surgical Oncology convened an Expert Panel to develop recommendat

98 rdiomyopathies/Congenital & Genetics, Cardio-Oncology, Coronary Disease & Interventions, Hypertension

99 with the adult Response Assessment in Neuro-Oncology criteria.

100 This potential microbiome-based oncology diagnostic tool warrants further exploration.

101 nd screened NCI drug libraries consisting of oncology drugs and natural compounds.

102 II library and 7 compounds from the approved oncology drugs set V library were found to exhibit antic

103 RI has drawn increasing interest in thoracic oncology due to the simultaneous acquisition of PET and

104 al trials, the European Association of Neuro-Oncology (EANO) recognized the need to provide updated g

105 Normal controls included chest CTs from oncology, emergency, and pneumonia-related indications.

106 The field of pediatric palliative oncology-encompassing primary palliative care provided b

107 heckpoint pathway have ushered in the modern oncology era.

108 (ASCO) and the European Society for Medical Oncology (ESMO) developed frameworks to evaluate the cli

109 biosimilars become more widely available in oncology, especially with recent regulatory approvals of

110 ed by the International Society of Pediatric Oncology European Neuroblastoma (SIOPEN) Biology Group.

111 inders (published in the Journal of Clinical Oncology) failed to improve adherence.

112 ews published in 2014 and 2016 in The Lancet Oncology focused on premarket and postmarket policies fo

113 g has emerged as a powerful clinical tool in oncology for identifying patients likely to respond to t

114 rly transformative applications in radiation oncology given the multifaceted and highly technical nat

115 odowska-Curie National Research Institute of Oncology, Gliwice Branch, were collected from a retrospe

116 Children's Oncology Group (COG) AALL0331 tested whether intensified

117 A primary objective of the Children's Oncology Group (COG) ANBL0532 phase III study was to ass

118 survey ascertaining adherence to Children's Oncology Group (COG) guidelines for survivors at high ri

119 The Children's Oncology Group (COG) protocol AALL0434 evaluated the saf

120 The Children's Oncology Group (COG) stratifies the treatment of patient

121 atients enrolled in the frontline Children's Oncology Group (COG) T-ALL clinical trial AALL1231, we d

122 revious treatment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 recruite

123 chemotherapy, and had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

124 were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 3 or less, w

125 d >= 75 years), baseline Eastern Cooperative Oncology Group (ECOG) performance status score, or depth

126 y neuroblastoma in the randomized Children's Oncology Group ANBL1221 trial.

127 Background The Eastern Cooperative Oncology Group and American College of Radiology Imaging

128 In this joint Children's Oncology Group and NRG Oncology multicentre, randomised,

129 idence of acute mucositis (Radiation Therapy Oncology Group and WHO scales) and 36-mo survival.

130 TMTV showed worse/higher Eastern Cooperative Oncology Group performance status (ECOG PS) >=2, stage I

131 h class A liver disease, Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1, and fol

132 ced breast cancer and an Eastern Cooperative Oncology Group performance status 0-2.

133 steroid requirement, and Eastern Cooperative Oncology Group performance status less than two.

134 aged >=18 years) with an Eastern Cooperative Oncology Group performance status of 0 or 1 and centrall

135 d 18 years or older with Eastern Cooperative Oncology Group performance status of 0 or 1 and histolog

136 ative breast cancer, and Eastern Cooperative Oncology Group performance status of 0 or 1 were eligibl

137 -C or IV melanoma and an Eastern Cooperative Oncology Group performance status of 0 or 1 were randoml

138 an tube carcinoma and an Eastern Cooperative Oncology Group performance status of 0 or 1 who had rece

139 Hodgkin lymphoma, had an Eastern Cooperative Oncology Group performance status of 0 or 1, and had rec

140 t or metastatic disease, Eastern Cooperative Oncology Group performance status of 0 or 1, and who had

141 8 years or older with an Eastern Cooperative Oncology Group performance status of 0 or 1, HER2-positi

142 adenocarcinoma, with an Eastern Cooperative Oncology Group performance status of 0 or 1, who had pro

143 ined histologically) and Eastern Cooperative Oncology Group performance status of 0 or 1, who had unl

144 a of the cervix, with an Eastern Cooperative Oncology Group performance status of 0 or 1, who were sc

145 8 years or older with an Eastern Cooperative Oncology Group performance status of 0 or 1.

146 ry clinical team, and an Eastern Cooperative Oncology Group performance status of 0 or 1.

147 atic disease, and had an Eastern Cooperative Oncology Group performance status of 0 or 1.

148 III breast cancer and an Eastern Cooperative Oncology Group performance status of 0 or 1.

149 systemic treatment; and Eastern Cooperative Oncology Group performance status of 0 or 1.

150 r metastatic STS who had Eastern Cooperative Oncology Group performance status of 0 to 2 and adequate

151 non-measurable disease, Eastern Cooperative Oncology Group performance status of 0, 1, or 2, and lef

152 Most (78%) had an Eastern Cooperative Oncology Group performance status of 0, and the median a

153 and the majority had an Eastern Cooperative Oncology Group performance status of 0-1 (142 [72%] of 1

154 t least 18 years with an Eastern Cooperative Oncology Group performance status of 0-1 recruited betwe

155 us cell carcinoma and an Eastern Cooperative Oncology Group performance status of 0-1) received cemip

156 all-cell lung cancer, an Eastern Cooperative Oncology Group performance status of 0-1, and a history

157 All patients had an Eastern Cooperative Oncology Group performance status of 0-2 and could have

158 IV ovarian cancer and an Eastern Cooperative Oncology Group performance status of 0-2 were randomly a

159 oclonal antibody with an Eastern Cooperative Oncology Group performance status of 0-2 were recruited,

160 transplantation, had an Eastern Cooperative Oncology Group performance status of 0-2, and had measur

161 gative breast cancer, an Eastern Cooperative Oncology Group performance status of 0-2, and had receiv

162 biliary tract cancer, an Eastern Cooperative Oncology Group performance status of 0-2, and had receiv

163 All patients had an Eastern Cooperative Oncology Group performance status of 0-2, and previous c

164 te myeloid leukaemia, an Eastern Cooperative Oncology Group performance status of 0-2, and were at hi

165 8 years or older with an Eastern Cooperative Oncology Group performance status of 0-2, life expectanc

166 sed chemotherapy, and an Eastern Cooperative Oncology Group performance status of 0-2.

167 multiple myeloma and an Eastern Cooperative Oncology Group performance status of 0-2.

168 none: 4.50, 1.33-15.28), Eastern Cooperative Oncology Group performance status of 2 or higher (status

169 apy regimens and with an Eastern Cooperative Oncology Group performance status of 2 or less had tumou

170 arge B-cell lymphoma, an Eastern Cooperative Oncology Group performance status of 2 or less, who had

171 e of therapy, and had an Eastern Cooperative Oncology Group performance status of 2 or less.

172 ears or older and had an Eastern Cooperative Oncology Group performance status of 2 or less.

173 line of therapy, with an Eastern Cooperative Oncology Group performance status of 2 or lower, and ade

174 roven diagnosis of SCLC, Eastern Cooperative Oncology Group performance status of 2 or lower, measura

175 atory agent), and had an Eastern Cooperative Oncology Group performance status of 2 or lower, were ra

176 a central laboratory; an Eastern Cooperative Oncology Group performance status score 0 or 1; and adeq

177 for advanced disease, an Eastern Cooperative Oncology Group performance status score of 0 or 1, and a

178 ating agents and with an Eastern Cooperative Oncology Group performance status score of 0-2.

179 rations, or both; and an Eastern Cooperative Oncology Group performance status score of 0-2.

180 nal criteria included an Eastern Cooperative Oncology Group performance status score of 2 or less and

181 ulatory drug; and had an Eastern Cooperative Oncology Group performance status score of 2 or lower.

182 maximum diameter) and an Eastern Cooperative Oncology Group performance status score of less than 3 (

183 ing the 5-point modified Eastern Cooperative Oncology Group scale and used Cox regression methods to

184 n and paclitaxel, and an Eastern Cooperative Oncology Group status of 0 or 1 were eligible for inclus

185 The high-risk stratum of Children's Oncology Group Study AALL1131 was designed to test the h

186 DSRCT specimens obtained from the Children's Oncology Group was sequenced using the Illumina HiSeq 20

187 tional Neuroblastoma Study Group, Children's Oncology Group, and Gesellschaft fuer Paediatrische Onko

188 tional Neuroblastoma Study Group, Children's Oncology Group, and Gesellschaft fuer Paediatrische Onko

189 Bristol-Myers Squibb, Children's Oncology Group, National Institutes of Health, Cookies f

190 Eastern Cooperative Oncology Group-American College of Radiology Imaging Net

191 oma European Study Group I/II and Children's Oncology Group.

192 Thus, tele-oncology has become a necessity to improve cancer care.

193 ree decades, a mainstay and goal of clinical oncology has been the development of therapies promoting

194 Despite certain shortcomings, tele-oncology has great potential to help cancer patients dur

195 While immuno-oncology has made significant advances in activating loc

196 Advances in molecular immunology and oncology have enhanced the role of p53 in both fields.

197 PI3Kdelta inhibitors initially developed for oncology have immune regulatory potential that could be

198 Recent molecular discoveries in oncology have spawned the development of an impressive a

199 recent publications in Science and Annals of Oncology highlight the potential benefits and limitation

200 d-derived suppressor cells (MDSCs) as a main oncology immunotherapeutic target.

201 based on nanomedicine has gained momentum in oncology in recent years, offering superior safety and e

202 nicians worldwide for head and neck surgical oncology in the context of the COVID-19 pandemic and in

203 This is particularly applicable to oncology in which treatment may be multimodal.

204 rketed covalent BTK inhibitors is limited to oncology indications based on their suboptimal kinase se

205 The Physical Sciences in Oncology Initiative was launched to integrate physics, m

206 amental cancer biology research and clinical oncology investigation.

207 HPK1 as a candidate target for novel immuno-oncology (IO) drug development that is centered on the u

208 Its impact on surgical oncology is still to elucidate.

209 This approach, especially in oncology, is often undermined when the cells make use of

210 logy and the European Society for Paediatric Oncology jointly developed clinically relevant and evide

211 mmune therapies) are profoundly changing the oncology landscape, bringing with them new requirements

212 have transformed the treatment landscape for oncology, leading to durable remissions in a subset of p

213 In the era of precision oncology, liquid biopsy techniques, especially the use o

214 trategy that may synergize with other immuno-oncology mechanisms and chemotherapies.

215 va Library developed for use in mathematical oncology modeling.

216 this joint Children's Oncology Group and NRG Oncology multicentre, randomised, open-label, phase 2 tr

217 basis for these American Society of Clinical Oncology/NCODA standards.

218 ers throughout the Translational Research in Oncology network.

219 The oncology nurse influence in saving lives through prevent

220 we highlight the contribution and impact of oncology nurses along the cancer care continuum.

221 Oncology nurses are at the heart of tackling the increas

222 Retention of experienced oncology nurses is crucial for future cancer control in

223 Globally, oncology nurses make a great positive difference to canc

224 al communication are essential components of oncology nursing care, which are often played down.

225 kforce consequences, and threats to standard oncology nursing practice are addressed here.

226 y in resource-constrained countries with few oncology nursing staff and continuing out-migration of n

227 Unfortunately, challenges to a robust oncology nursing workforce include nursing shortages, re

228 Supportive care, the central pillar of oncology nursing, enables and empowers people to self-ma

229 cessing, Informatics, Neural Networks, Neuro-Oncology, Oncology, Treatment Effects, Tumor Response Su

230 veness have been routinely incorporated into oncology or palliative care.

231 senters who published in Journal of Clinical Oncology or who presented an abstract at the ASCO 2018 A

232 Nearly one-third of hematology-oncology outpatients were prescribed antibiotics for URI

233 Equally rapid progress in mathematical oncology over this time period has often come in the for

234 Keywords: Abdomen/GI, Genetic Defects, Oncology, Pancreas Supplemental material is available fo

235 2018, the National Cancer Institute and NRG Oncology partnered for the first time to host a joint wo

236 All were among oncology patients at clinic A.

237 ple is the use of PARP inhibitors (PARPi) in oncology patients with BRCA mutations.

238 By 31 December 2018, 52 of 151 (34%) oncology patients with chemotherapy ports accessed at cl

239 Chemotherapy is central to oncology, perceived to operate only on prolific cancerou

240 multicomponent intervention, often led by an oncology pharmacist, and also included patient education

241 Keywords: Head/Neck, Oncology, Pharynx, Staging (C) RSNA, 2020.

242 nsensus statements on head and neck surgical oncology practice.

243 oring these characteristics is a priority in oncology practice.

244 , done in 246 academic centres and community oncology practices in 41 countries, patients aged 18 yea

245 rticipants were recruited from 272 community oncology practices or academic medical centres in the US

246 and unmet needs, which were not addressed by oncology, primary care or advocacy professionals.

247 Colorectal cancer survivors relied on oncology professionals for cancer-related support and ex

248 LTSWhole-exome sequencing within a precision oncology program identified an activating mutation (p.As

249 Cardio-oncology programs implement a clinical assessment to cur

250 cancer care; (3) advance policies to ensure oncology providers have sufficient resources to provide

251 anel of medical oncology, surgery, radiation oncology, radiology, pathology, and advocacy experts to

252 The Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group, consisting of an interna

253 cer Network and American Society of Clinical Oncology recommend consideration of the use of echocardi

254 rding to recent Response Assessment in Neuro-Oncology recommendations, PET overcomes this limitation.

255 Precision oncology relies on accurate discovery and interpretation

256 s well as with otolaryngology and hematology oncology reports addressing Turicella otitidis specifica

257 coma treated at seventeen Pediatric Surgical Oncology Research Collaborative institutions between 200

258 AgNPs' application in oncology research is a new, open, and promising field an

259 l applications of tumor organoids for immuno-oncology research, immunotherapy modeling, and precision

260 elationships for authors who report clinical oncology research.

261 NRG Oncology/RTOG 9802 (ClinicalTrials.gov Identifier: NCT00

262 rresponding molecular alterations within NRG Oncology/RTOG 9802.

263 ntibiotic prescribing for URIs in outpatient oncology settings merits further study.

264 amework for palliative care of caregivers in oncology settings.

265 ES framework to guide care for caregivers in oncology settings: Considering caregivers as part of the

266 blockade represents a promising approach in oncology, showing antitumor activities in various cancer

267 Many oncology societies and health ministries have issued gui

268 Recently, in immune-oncology, specific microbial taxa have been described to

269 Network (NCCN) and ASCO/Society of Surgical Oncology (SSO) guidelines and the Memorial Sloan Ketteri

270 This survey showed how surgical oncology suffered remarkable reduction of the activity r

271 patients undergoing cardiac, orthopedic, and oncology surgeries.

272 Oncology convened an Expert Panel of medical oncology, surgery, radiation oncology, radiology, pathol

273 fied a highly effective bioPROTAC against an oncology target, proliferating cell nuclear antigen (PCN

274 tes, neurodegenerative diseases and numerous oncology targets(1).

275 tions, based on a small set of 102 validated oncology targets, recovered the majority of known drug t

276 ative care provided by the multidisciplinary oncology team as well as subspecialty palliative care pr

277 The patient was evaluated by the surgical oncology team, who believed that the parotid mass and ce

278 care teams can enhance the care delivered by oncology teams.

279 financed by the European Society of Surgical Oncology, the Champalimaud Foundation Lisbon, the Bas Mu

280 Oncology, the field where Big Data collection and utiliz

281 Despite its widespread use in oncology, the PET radiotracer (18)F-FDG is ineffective f

282 ls are one of the fastest growing classes of oncology therapeutics, with eight ADCs and two immunotox

283 /CD3-bispecific T-cell engager (BiTE) immuno-oncology therapy for the treatment of B-cell malignancie

284 International Classification of Disease for Oncology, Third Edition, codes for both morphologic feat

285 encing (WGS) costs are falling, yet, outside oncology, this information is seldom used in adult clini

286 ngineering with cancer research and clinical oncology through education, outreach, and collaboration.

287 pplying novel technology developed in immuno-oncology to cardiovascular biology and disease may be tr

288 Radiation Oncology, and Society of Urologic Oncology to conduct a systematic review of the literatur

289 Many medical treatments, from oncology to psychiatry, can lower white blood cell count

290 oltage electrical pulses (HVEPs) in clinical oncology to treat solid tumors with irreversible electro

291 nformatics, Neural Networks, Neuro-Oncology, Oncology, Treatment Effects, Tumor Response Supplemental

292 pursued as a therapeutic target in clinical oncology trials, its effects on metastasis, the principa

293 In precision oncology, two major strategies are being pursued for pre

294 on of step-down units and general hematology-oncology units in adult 2017 baseline SAAR models and th

295 In many areas of oncology, we lack sensitive tools to track low-burden di

296 Between 2007 and 2020, 33 biosimilars for oncology were approved by the European Medicines Agency

297 specific small-molecule inhibitor tracers in oncology will be discussed along with potential nononcol

298 The Response Assessment in Neuro-Oncology working group developed response criteria for a

299 The Response Assessment in Pediatric Neuro-Oncology working group, consisting of an international p

300 Service Award, American Society of Clinical Oncology Young Investigator Award, MSK's Ludwig Center,